PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentA tragic death that should not deter gene therapy researchers

BioNews

A tragic death that should not deter gene therapy researchers

Published 18 June 2009 posted in Comment and appears in BioNews 28

Author

Juliet Tizzard

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Jesse Gelsinger's parents are no doubt still reeling from the news of their son's death. But as they try to get on with the rest of their lives, a public and professional debate about why he died is raging in the United States. Jesse, who was 18 years old, died...

Jesse Gelsinger's parents are no doubt still reeling from the news of their son's death. But as they try to get on with the rest of their lives, a public and professional debate about why he died is raging in the United States. Jesse, who was 18 years old, died after experimental genetic therapy to treat a rare genetic disease, called ornithine transcarbamylase (OTC) deficiency, which had blighted him all his life. Now, a full-scale enquiry is taking place to examine the circumstances of Jesse's death.

The tragedy of the situation hardly needs stating. When someone dies whilst taking part in research which may help others, the sacrifice the participant made is poignant enough. But in Jesse Gelsinger's case, the sacrifice was particularly acute. He had a mild form of the disease and his symptoms had been brought under control by a drug regimen and a strict, non-protein diet. Jesse took part in the trial because he wanted to help other people who suffer from OTC deficiency. His own need for a cure was, although evident, less pressing than that of other sufferers.


Anyone taking part in a clinical trial has to take into account the risks and benefits of doing so. Participants have to balance their desire to help advance medical science with a concern for their own health and wellbeing. No doubt, Jesse Gelsinger did this: he weighed up the pros and cons and decided to take part - along with 17 other OTC sufferers - in the gene therapy trial.


In the public debate in the US, questions have already been asked about the safety of gene therapy and about the process by which clinical trials are approved. The results of the trial will need to be scientifically assessed and the approval process should be monitored, to make sure it's systems are rigorous. But ultimately, the scientific community should not be deterred from continuing with gene therapy research and trials. More importantly, the public should not lose faith in the potential of gene therapy to treat a range of debilitating genetic diseases - even though current work may take some time to bear fruit. Some people have lost their lives for the sake of the advancement of treatments that are now commonplace. Let's hope that, some years from now, gene therapy is regarded as a routine intervention and people like Jesse Gelsinger can live as normal a life as the rest of us.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
8 May 2018 • 3 minutes read

Video Review: The Code by Retro Report with STAT

by Charlott Repschläger

Personalised medicine is a topic that pops up frequently in the news and has been for what feels like a long time...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene therapy trial death under investigation

by Ailsa Stevens

Last month a gene therapy trial for arthritis, carried out by US company Targeted Genetics, was halted when following the death of 36-year-old participant Jolee Mohr. Although the exact cause of her death is still unknown, the usually mild fungal infection found throughout Mrs Mohr's body...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene therapy researchers fined over trial participant's death

by BioNews

Two US institutions that ran a gene therapy trial in which a teenager died in 1999 agreed to pay more than $1 million in a civil settlement last week. The government had alleged that the researchers, based at the University of Pennsylvania and the Children's National Medical Center, had failed...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« More silly talk of men having babies

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Recent
27 June 2022 • 4 minutes read

Thirty years of PET: our 'Fertility, Genomics and Embryo Research' report

27 June 2022 • 5 minutes read

Children's rights and donor conception: What next?

20 June 2022 • 4 minutes read

The problems with lifting donor anonymity earlier

20 June 2022 • 6 minutes read

An adaptive act: How should human fertilisation and embryology legislation respond to scientific and technological change?

13 June 2022 • 1 minute read

A new look for BioNews

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856